SQZ Biotechnologies Co. (SQZ): Price and Financial Metrics

SQZ Biotechnologies Co. (SQZ): $3.37

-0.16 (-4.53%)

POWR Rating

Component Grades













Add SQZ to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where SQZ ranks best; there it ranks ahead of 77.47% of US stocks.
  • SQZ's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • SQZ ranks lowest in Momentum; there it ranks in the 4th percentile.

SQZ Stock Summary

  • SQZ Biotechnologies Co's stock had its IPO on October 30, 2020, making it an older stock than merely 2.01% of US equities in our set.
  • Of note is the ratio of SQZ Biotechnologies Co's sales and general administrative expense to its total operating expenses; merely 11.81% of US stocks have a lower such ratio.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SQZ comes in at -40.7% -- higher than that of only 10.54% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SQZ Biotechnologies Co are EIGR, MEIP, CTMX, GLYC, and LPTX.
  • SQZ's SEC filings can be seen here. And to visit SQZ Biotechnologies Co's official web site, go to www.sqzbiotech.com.

SQZ Valuation Summary

  • SQZ's EV/EBIT ratio is -3.5; this is 111.95% lower than that of the median Healthcare stock.
  • Over the past 44 weeks, SQZ's price/earnings ratio has gone up 2.4.
  • Over the past 44 weeks, SQZ's EV/EBIT ratio has gone up 2.6.

Below are key valuation metrics over time for SQZ.

Stock Date P/S P/B P/E EV/EBIT
SQZ 2021-08-31 20.1 2.4 -5.8 -3.5
SQZ 2021-08-30 20.1 2.4 -5.8 -3.6
SQZ 2021-08-27 20.4 2.5 -5.9 -3.6
SQZ 2021-08-26 19.2 2.3 -5.5 -3.3
SQZ 2021-08-25 18.3 2.2 -5.3 -3.0
SQZ 2021-08-24 18.2 2.2 -5.3 -3.0

SQZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SQZ has a Quality Grade of C, ranking ahead of 53% of graded US stocks.
  • SQZ's asset turnover comes in at 0.082 -- ranking 279th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SQZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.082 1 -1.099

SQZ Price Target

For more insight on analysts targets of SQZ, see our SQZ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.67 Average Broker Recommendation 1.2 (Strong Buy)

SQZ Stock Price Chart Interactive Chart >

Price chart for SQZ

SQZ Price/Volume Stats

Current price $3.37 52-week high $16.17
Prev. close $3.53 52-week low $2.73
Day low $3.20 Volume 248,200
Day high $3.57 Avg. volume 329,255
50-day MA $3.42 Dividend yield N/A
200-day MA $8.06 Market Cap 94.86M

SQZ Biotechnologies Co. (SQZ) Company Bio

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

SQZ Latest News Stream

Event/Time News Detail
Loading, please wait...

SQZ Latest Social Stream

Loading social stream, please wait...

View Full SQZ Social Stream

Latest SQZ News From Around the Web

Below are the latest news stories about SQZ Biotechnologies Co that investors may wish to consider to help them evaluate SQZ as an investment opportunity.

SQZ: IND Cleared for Enhanced APCs

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT Since Our Last Update Since our last update , SQZ Biotechnologies Company (NYSE:SQZ) has made progress on the regulatory front with an investigational new drug (IND) clearance, the addition of strategic advisor John Maraganore, Ph.D. and the publication of preclinical research on SQZ APCs. Highlights since our last update: ➢

Yahoo | February 7, 2022

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation

WATERTOWN, Mass., February 01, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of comprehensive preclinical research on the company’s ability to engineer multiple immune cell types to drive MHC-I antigen presentation, a critical advance in the ability to drive a patient’s killer T cells to fight multiple diseases. The cell engineering findings, published online and in the February 15t

Yahoo | February 1, 2022

SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors

WATERTOWN, Mass., January 24, 2022--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV, authorizing the company to proceed with initiating a Phase 1/2 clinical trial of the novel cell therapy candidate. The company plans to initiate its COMMANDER-001 Phase 1/2 clinical trial of

Yahoo | January 24, 2022

Bangor Savings Bank Buys Vanguard Intermediate-Term Government Bond ETF, Global Payments Inc, ...

Bangor, ME, based Investment company Bangor Savings Bank (Current Portfolio) buys Vanguard Intermediate-Term Government Bond ETF, Global Payments Inc, Vanguard Tax-Exempt Bond ETF, International Business Machines Corp, Newell Brands Inc, sells Consumer Discretionary Select Sector SPDR, BP PLC, Philip Morris International Inc, Vanguard Intermediate-Term Corporate Bond ETF, iShares ESG Aware U.S.

Yahoo | January 20, 2022

SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor

WATERTOWN, Mass., January 06, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor.

Yahoo | January 6, 2022

Read More 'SQZ' Stories Here

SQZ Price Returns

1-mo -4.80%
3-mo -29.05%
6-mo -64.79%
1-year -76.30%
3-year N/A
5-year N/A
YTD -62.26%
2021 -69.19%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4654 seconds.